Professional Marketing briefs: September 2013

Share this article:
Herve Gisserot
Herve Gisserot

Vivus' new executive leadership has walked into a upswing. Sales of the prescription weight-loss drug Qsymia have started to rise, with a 27% growth between its 2012 approval and July, reports Pharmalot. The change isn't due to management, which showed up at the end of July. Instead, it reflects the retail-level stocking that went into effect. The medication had been limited to mail order.

Bristol-Myers Squibb says it is putting more power behind its ­Eliquis promotion. The drug maker wouldn't offer specifics, but told investors converting doctors to Eliquis works best when docs have time to sit with the full data set and create ­opportunities—such as education—to provide settings and information that can turn doctors “into believers and ­trialists.”

Herve Gisserot is the new head of Glaxo­SmithKline's China business, replacing Mark Reilley, who will stay with the company. The reorg follows allegations that the company bribed doctors, hospitals and government officials to juice sales. GSK is just one of several companies China is looking into. A spokesman told the Wall Street Journal that Reilly will help shape GSK's response to allegations of misconduct.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...